<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618783</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-sIPV-1001-1</org_study_id>
    <nct_id>NCT04618783</nct_id>
  </id_info>
  <brief_title>Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization</brief_title>
  <official_title>Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization Against Multiple Individual Wild and Vaccine-derived Polioviruses, Supplementary Study of a Phase 2 Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a supplementary study of an already finished randomised, double-blinded, and&#xD;
      placebo controlled phase 2 clinical trial of an Sabin strain inactivated poliovirus vaccine&#xD;
      (sIPV) manufactured by Sinovac Biotech Ltd., Beijing China. The purpose of this study is to&#xD;
      evaluate the cross-neutralization capacity of the serum immuned by the investigational sIPV&#xD;
      against 10 individual virus strains.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a open-labelled study conducted based on an already finished phase 2 study of&#xD;
      the investigational sIPV in 600 healthy infants aged 2-months old. The purpose of this study&#xD;
      is to evaluate the cross-neutralization capacity of the serum immuned by the investigational&#xD;
      sIPV against 10 individual virus strains. Paired pre-immune and post-immune serum from 250&#xD;
      participants of the phase 2 trial, with 50 in each group including the low-, medium- and&#xD;
      high- dosage group, control wild poliovirus vaccine (wIPV) group and control sIPV group, was&#xD;
      selected and sent to China Center for Disease Control and Prevention (CDC) for the&#xD;
      cross-neutralization assay to determine the neutralizing antibody titer against 10 individual&#xD;
      virus strains including Sabin strains (type 1, 2, and 3), Salk strains (Mahoney, MEF-1, and&#xD;
      Saukett), cVDPV (type 1, 2, and 3) and Xinjiang wild strain of type 1(Xinjiang wIPV1).&#xD;
&#xD;
      All the subjects in this study had been vaccinated at the schedule of month 0,1, and 2 in the&#xD;
      phase 2 clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2019</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunity index of seroconversion rate</measure>
    <time_frame>One month after three doses of vaccination</time_frame>
    <description>The seroconversion rates of neutralizing antibody against 10 individual virus strains (Sabin 1, Sabin2， Sabin 3, Mahoney 1, MEF-1, Saukett, cVDPV1, cVDPV2, cVDPV3, and Xinjiang wIPV1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunity index of geometric mean titer (GMT)</measure>
    <time_frame>One month after three doses of vaccination</time_frame>
    <description>The GMT of neutralizing antibody against 10 individual virus strains (Sabin 1, Sabin2， Sabin 3, Mahoney 1, MEF-1, Saukett, cVDPV1, cVDPV2, cVDPV3, and Xinjiang wIPV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunity index of geometric mean ratio (GMR)</measure>
    <time_frame>One month after three doses of vaccination</time_frame>
    <description>The GMR of neutralizing antibody against 10 individual virus strains (Sabin 1, Sabin2， Sabin 3, Mahoney 1, MEF-1, Saukett, cVDPV1, cVDPV2, cVDPV3, and Xinjiang wIPV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunity index of seropositivity rate</measure>
    <time_frame>One month after three doses of vaccination</time_frame>
    <description>The seropositivity rate of neutralizing antibody against 10 individual virus strains (Sabin 1, Sabin2， Sabin 3, Mahoney 1, MEF-1, Saukett, cVDPV1, cVDPV2, cVDPV3, and Xinjiang wIPV1)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>Low-dosage experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dosage experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dosage experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control wIPV group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three doses of control wIPV, vaccinated within one-month interval between doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control sIPV group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three doses of control sIPV, vaccinated within one-month interval between doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses</intervention_name>
    <description>Antigen content: 7.5, 22.5, and 22.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose</description>
    <arm_group_label>Low-dosage experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses</intervention_name>
    <description>Antigen content: 15, 45, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose</description>
    <arm_group_label>Medium-dosage experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses</intervention_name>
    <description>Antigen content: 22.5, 67.5, and 67.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose</description>
    <arm_group_label>High-dosage experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Three doses of control wIPV, vaccinated within one-month interval between doses</intervention_name>
    <description>Antigen content: 40, 8, and 32 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose</description>
    <arm_group_label>Control wIPV group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Three doses of control sIPV, vaccinated within one-month interval between doses</intervention_name>
    <description>Antigen content: 30, 32, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose</description>
    <arm_group_label>Control sIPV group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants of the already finished phase 2 clinical trial;&#xD;
&#xD;
          -  Subjects who received the three-doses full schedule vaccination required in the phase&#xD;
             2 tril and can provide the backup paired pre-immune and post-immune serum collected in&#xD;
             the phase trial;&#xD;
&#xD;
          -  Provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuemei Hu, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pizhou Center for Disease Control and Prevention</name>
      <address>
        <city>Pizhou</city>
        <state>Jiangsu</state>
        <zip>221300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

